Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $7.75 USD
Change Today +0.013 / 0.17%
Volume 1.6M
ARRY On Other Exchanges
Symbol
Exchange
NASDAQ GM
Stuttgart
As of 3:49 PM 06/2/15 All times are local (Market data is delayed by at least 15 minutes).

array biopharma inc (ARRY) Snapshot

Open
$7.75
Previous Close
$7.74
Day High
$7.85
Day Low
$7.62
52 Week High
03/5/15 - $8.59
52 Week Low
10/13/14 - $2.98
Market Cap
1.1B
Average Volume 10 Days
1.7M
EPS TTM
$-0.47
Shares Outstanding
141.1M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ARRAY BIOPHARMA INC (ARRY)

array biopharma inc (ARRY) Related Bloomberg News

View More Bloomberg News

array biopharma inc (ARRY) Related Businessweek News

No Related Businessweek News Found

array biopharma inc (ARRY) Details

Array BioPharma Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule drugs to treat patients with cancer in North America, Europe, and the Asia Pacific. The company’s products in Phase III clinical trials include Binimetinib and Encorafenib for the treatment of cancer. Its clinical programs in Phase II clinical trial include ARRY-797, a p38 program for Lamin A/C-related dilated cardiomyopathy; and ARRY-502, a CRTh2 antagonist to treat Th2-driven allergic disease. The company’s proprietary programs also comprise Filanesib, a kinesin spindle protein inhibitor for multiple myeloma; and ARRY-614, a p38/Tie2 dual inhibitor for myelodysplastic syndromes. Its partnered clinical programs include various drug candidates; Selumetinib, an MEK inhibitor for cancer; ASLAN001/ARRY-543, an HER2/EGFR inhibitor for gastric cancer; Ipatasertib/GDC-0068, an AKT inhibitor for cancer; VTX-2337, a toll-like receptor for cancer; and Danoprevir, a Hepatitis C virus protease inhibitor. The company’s partnered clinical programs also comprise LY2606368, an Chk-1 inhibitor for cancer; GDC-0575, an Chk-1 inhibitor for cancer; ARRY-380/ONT-380, an HER2 inhibitor for breast cancer,; GDC-0994, an ERK inhibitor for cancer; and LOXO-101, an PanTrk inhibitor for cancer. It has collaborations with Celgene Corporation; Celgene Alpine Investment Co., LLC; Genentech, Inc.; Loxo Oncology, Inc; Novartis International Pharmaceutical Ltd.; and Oncothyreon Inc. The company was founded in 1998 and is headquartered in Boulder, Colorado.

198 Employees
Last Reported Date: 08/15/14
Founded in 1998

array biopharma inc (ARRY) Top Compensated Officers

Chief Executive Officer and Director
Total Annual Compensation: $548.8K
Chief Operating Officer
Total Annual Compensation: $343.8K
Compensation as of Fiscal Year 2014.

array biopharma inc (ARRY) Key Developments

Array BioPharma Inc. Presents at Jefferies 2015 Global Healthcare Conference, Jun-02-2015 01:30 PM

Array BioPharma Inc. Presents at Jefferies 2015 Global Healthcare Conference, Jun-02-2015 01:30 PM. Venue: The Grand Hyatt Hotel, New York, New York, United States. Speakers: Ron Squarer, Chief Executive Officer and Director.

Array BioPharma, Inc. Presents at Bank of America Merrill Lynch 2015 Health Care Conference, May-14-2015 12:00 PM

Array BioPharma, Inc. Presents at Bank of America Merrill Lynch 2015 Health Care Conference, May-14-2015 12:00 PM. Venue: Encore at the Wynn, 3131 S Las Vegas Blvd, Las Vegas, Nevada, United States. Speakers: Ron Squarer, Chief Executive Officer and Director.

Array BioPharma, Inc. Announces Unaudited Earnings Results for the Third Quarter and Nine Months Ended March 31, 2015

Array BioPharma, Inc. announced unaudited earnings results for the third quarter and nine months ended March 31, 2015. For the quarter, the company's total revenue was $6.6 million compared with $7.8 million a year ago. Income from operations was $54.5 million compared with loss of $22.5 million a year ago. Net income was $58.3 million or $0.37 per diluted share compared with net loss of $24.9 million or $0.20 per diluted share a year ago. For the nine months, the company's total revenue was $39.6 million compared with $36.1 million a year ago. Income from operations was $23.3 million compared with loss of $49.8 million a year ago. Net income was $22.1 million or $0.16 per diluted share compared with net loss of $57.0 million or $0.47 per diluted share a year ago.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ARRY:US $7.75 USD +0.013

ARRY Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Arena Pharmaceuticals Inc $4.19 USD +0.06
CTI BioPharma Corp $2.13 USD -0.045
Evotec AG €3.68 EUR -0.063
Exelixis Inc $3.35 USD -0.09
Progenics Pharmaceuticals Inc $5.57 USD -0.025
View Industry Companies
 

Industry Analysis

ARRY

Industry Average

Valuation ARRY Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 23.7x
Price/Book 21.7x
Price/Cash Flow NM Not Meaningful
TEV/Sales 17.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ARRAY BIOPHARMA INC, please visit www.arraybiopharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.